# Trilliome

> Trilliome is a Swiss healthcare company pioneering precision bioactives — shelf-stable, plant-derived small molecules that modulate the gut ecosystem for healthy aging, at milligram doses, supplied to consumer-health brands as B2B ingredients. Its platform, Teroka, couples a wetlab data-generation engine with a computational engine to learn how to steer the gut microbiome with species-level precision. First two products: TRI-01 (a precision gut-brain activator) and TRI-04 (a low-molecular-weight prebiotic fibre).

## Platform & ingredients
- [The platform (Teroka)](https://www.trilliome.com/platform/): The repeatable discovery engine — a closed wetlab + computational loop producing precision bioactives and their combinations.
- [Ingredients](https://www.trilliome.com/ingredients/): The precision-bioactive portfolio (TRI-01, TRI-04) plus a development pipeline.
- [TRI-01](https://www.trilliome.com/ingredients/tri-01/): Shelf-stable active that selectively induces a named four-species consortium of keystone gut bacteria (Agathobaculum butyriciproducens, Coprococcus catus, Anaerostipes hadrus, Faecalibacillus intestinalis) — keystone species whose beneficial functions reach beyond butyrate (neuroactive and immunomodulatory factors; Agathobaculum modulates neuroinflammation); milligram dose; all formats; Self-Affirmed GRAS pathway.
- [TRI-04](https://www.trilliome.com/ingredients/tri-04/): Low-molecular-weight, water-soluble prebiotic fibre supporting the gut's butyrate-producing bacteria; metabolic-health (GLP-1 axis) claim path under study.
- [Pipeline](https://www.trilliome.com/ingredients/pipeline/): Further nutraceutical and cosmeceutical actives in development.

## Science & evidence
- [How it works](https://www.trilliome.com/science/how-it-works/): Mechanism — activating keystone gut species already present in the gut rather than delivering live cells; these species produce a broad repertoire beyond butyrate.
- [The evidence](https://www.trilliome.com/science/evidence/): Ex-vivo induction data (up to +96-fold for the lead species in combination) and the planned clinical program; ex-vivo, not yet clinical.
- [Quality & manufacturing](https://www.trilliome.com/science/quality/): Green, food-grade extraction from upcycled side-streams; specification, CoA, regulatory pathway.
- [IP & defensibility](https://www.trilliome.com/ip/): Priority EPO patent application with a favourable Search Opinion on the cognitive indication; trade-secret process; a compounding data moat.

## Company
- [Company](https://www.trilliome.com/company/): A Swiss healthcare company founded by Patrick Guye, PhD (CEO) and Tim Mak, PhD (CBO); advisory board from leading nutrition, pharma and ingredient companies; 7 signed letters of intent; three 2025 industry awards.
- [For partners](https://www.trilliome.com/partners/): How brands engage Trilliome for precision bioactive ingredients.
- [For investors](https://www.trilliome.com/investors/): The platform thesis, moat, traction, and team.

## Editorial
- [Insights](https://www.trilliome.com/insights/): Thought leadership on the gut-brain axis, precision microbiome modulation, the biology of keystone gut species, and evidence standards for functional ingredients.
- [News](https://www.trilliome.com/news/): Company updates — awards, events, milestones, releases.